Tesamorelin: The FDA-Approved GHRH Analog for Visceral Fat and Body Composition Research

Tesamorelin (brand name Egrifta) holds a unique position among growth hormone secretagogues — it's the only GHRH analog with current FDA approval for a specific clinical indication. Approved in 2010 for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, Tesamorelin is a 44-amino acid GHRH analog with a trans-3-hexenoic acid modification that improves metabolic stability. Published research extends well beyond HIV lipodystrophy into general visceral fat reduction, liver fat, cognitive function, and body composition optimization.

The Visceral Fat Problem

Visceral adipose tissue (VAT) — fat stored around the abdominal organs — is metabolically distinct from subcutaneous fat. VAT is more metabolically active, releases more pro-inflammatory cytokines, is more strongly associated with cardiovascular disease and insulin resistance, and is more resistant to diet and exercise interventions. Published research has established visceral fat as an independent risk factor for cardiovascular events, type 2 diabetes, and all-cause mortality — even in individuals with normal BMI.

Tesamorelin's FDA approval was based on published clinical trials showing significant reduction in visceral fat as measured by CT scan — the gold standard for compartment-specific fat quantification. The VAT reduction was selective: visceral fat decreased while subcutaneous fat was relatively preserved, suggesting a mechanism that specifically targets the visceral compartment.

Mechanism: GH-Mediated Lipolysis

Tesamorelin stimulates pituitary GH release, which in turn activates lipolysis (fat breakdown) in adipose tissue through GH receptor-mediated signaling. Visceral adipocytes express more GH receptors than subcutaneous adipocytes, which may explain the preferential visceral fat reduction. GH-stimulated lipolysis involves activation of hormone-sensitive lipase, promoting triglyceride hydrolysis and fatty acid release for oxidation.

Liver Fat Research

Published studies demonstrated Tesamorelin reduced hepatic fat content in patients with NAFLD — a finding with implications beyond the HIV lipodystrophy indication. The mechanism likely involves increased hepatic fatty acid oxidation driven by GH-mediated metabolic effects, combined with reduced visceral fat delivery of free fatty acids to the liver through the portal circulation. Some published data suggested Tesamorelin also reduced liver fibrosis markers, though longer-term studies are needed to confirm anti-fibrotic effects.

Cognitive Effects

An unexpected finding in published Tesamorelin research was improvement in cognitive function — specifically executive function and verbal memory — in middle-aged and older adults. The mechanism may involve IGF-1's neurotrophic effects, improved cerebrovascular function, or GH's direct effects on hippocampal neurons. Published MRI studies showed preservation of brain volume in Tesamorelin-treated subjects compared to controls over 6-12 month periods.

Body Composition Beyond HIV

Published research has explored Tesamorelin for general age-related body composition changes — the redistribution of fat from subcutaneous to visceral depots and the loss of lean mass that characterizes aging. Results showed improved lean-to-fat ratios, reduced waist circumference, and improved metabolic markers (triglycerides, cholesterol) independent of HIV status.

Comparison to Other GH Secretagogues

Tesamorelin differs from Sermorelin and CJC-1295 primarily in its stability and clinical validation. As a 44-amino acid analog (compared to Sermorelin's 29), it retains more of the native GHRH structure. The trans-3-hexenoic acid modification provides greater resistance to DPP-4 degradation than unmodified Sermorelin. And as the only FDA-approved GHRH analog with Phase 3 clinical trial data, its evidence base for efficacy and safety exceeds that of other GH secretagogues.